Boehringer Ingelheim has reported new Phase III data for survodutide, its once-weekly dual GLP-1/glucagon receptor agonist for obesity, highlighting reductions in body weight, visceral fat and liver fat. The results, presented at the American Diabetes Association Scientific Sessions, strengthen the company’s case that survodutide could offer a differentiated profile in metabolic disease, although gastrointestinal tolerability remains a key question.
AlzeCure shares soar over 300% after Eli Lilly strikes Alzheimer’s deal worth over $1bn
Latest NewsSwedish biotech AlzeCure Pharma entered a collaboration and licensing agreement with Eli Lilly, granting the biopharma giant global rights to its Alzheimer’s disease candidate Alzstatin (ACD680). Under the terms of the deal, Alzecure will receive $10 million upfront and could receive more than $1 billion in development and commercial milestone payments, in addition to tiered royalties on future sales.
Boehringer/Zealand obesity drug delivers Phase III weight loss, but side effects raise questions
Latest NewsBoehringer Ingelheim has reported new Phase III data for survodutide, its once-weekly dual GLP-1/glucagon receptor agonist for obesity, highlighting reductions in body weight, visceral fat and liver fat. The results, presented at the American Diabetes Association Scientific Sessions, strengthen the company’s case that survodutide could offer a differentiated profile in metabolic disease, although gastrointestinal tolerability remains a key question.
Bial drops pariceract after Phase IIb failure in GBA-associated Parkinson’s
Latest NewsPortuguese drugmaker BIAL has discontinued development of BIA 28-6156, also known as pariceract, after a Phase IIb study failed to show that the oral therapy could slow progression in patients with GBA-associated Parkinson’s disease. The readout marks a setback for one of the more advanced attempts to turn Parkinson’s genetics into a disease-modifying therapy.
GSK taps Engitix’s platform in liver fibrosis deal worth up to £44.5m upfront
Latest NewsLondon-based Engitix Ltd has entered a strategic research collaboration and option agreement with GSK to discover and validate new therapeutic targets for liver fibrosis regression, adding another pharma partnership to its extracellular matrix-driven drug discovery platform.
Next-gen oligonucleotides to transform patient care
Sponsored PublicationsSecarna Pharmaceuticals is redefining the discovery and development of oligonucleotide therapeutics to address hard-to-treat disorders. The Company is planning to raise a Series A to advance its lead oncology asset, SECN-15, into Phase 1/2. Secarna is supported by global partnerships that validate their expertise and accelerate development.
Roche bets on BTK degradation in $2.3bn Nurix deal
Latest NewsSwiss pharma giant Roche has signed a global licensing and collaboration agreement with US biotech Nurix Therapeutics to co-develop and co-commercialise bexobrutideg, an oral Bruton’s tyrosine kinase (BTK) degrader being developed for B-cell malignancies and potentially for immunology and neurology indications.
ADC Therapeutics stock halves after Zynlonta Phase III records three times more deaths than control arm
Latest NewsSwiss ADC specialist ADC Therapeutics has reported a statistically positive Phase III result for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma, but a higher rate of fatal adverse events in the experimental arm has overshadowed the efficacy readout and triggered a sharp investor backlash.
Biotechnology expert joins CDMO
AppointmentsDr Ralf Otto, a former manager at Boehringer Ingelheim and Rentschler, has been appointed as the new Chief Operating Officer of the Polish company Rezon Bio.
Lilly and Boehringer pause $2bn German investments over planned drug-spending curbs
Latest NewsThe announcements came almost simultaneously and send a clear signal to policymakers and the industry: both US pharmaceutical group Eli Lilly and German-based Boehringer Ingelheim are calling planned investments in Germany into question, citing the country’s healthcare policy framework.
Ona Therapeutics bags $86.6m Series B for stealth ADC push
Latest NewsBarcelona-based Ona Therapeutics has raised US$86.6m in a Series B financing to advance a new generation of antibody-drug conjugates into clinical development.